Classical Lobular Carcinoma In Situ Arising From an Intraductal Papilloma of the Breast: A Case Report

2021 ◽  
pp. 106689692098521
Author(s):  
Nah Ihm Kim ◽  
Min Ho Park ◽  
Ji Shin Lee
Keyword(s):  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Intraductal Papilloma ◽  
Lobular Neoplasia ◽  
Lobular Carcinoma In Situ ◽  
Optimal Care ◽  
Proliferative Lesion ◽  
New Criterion ◽  
Benign Mass

Intraductal papilloma of the breast is a benign, mass-forming, proliferative lesion with a papillary architecture confined within a duct. Lobular neoplasia can rarely arise from an intraductal papilloma of the breast. In this article, we report the morphologic features of a rare case of classical LCIS (lobular carcinoma in situ) arising from an intraductal papilloma in a 76-year-old woman. The monomorphic dyscohesive cells were present between the myoepithelial and luminal epithelial layer in the periphery of the papilloma. These cells partially obliterated the spaces between the papillae forming solid sheets. The monomorphic dyscohesive cells showed lack of E-cadherin expression and uniform staining for estrogen receptor. We review the histologic differential diagnosis and stress the importance of correct classification to ensure optimal care for patients. We also propose a new criterion for the distinction of lobular neoplasia within a papilloma.

Lobular Neoplasia of the Breast: An Update

2009 ◽  
Vol 133 (7) ◽  
pp. 1116-1120 ◽  
Author(s):  
Alejandro Contreras ◽  
Husain Sattar
Keyword(s):  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Lobular Neoplasia ◽  
Therapeutic Interventions ◽  
High Grade ◽  
Lobular Carcinoma In Situ ◽  
Molecular Studies ◽  
Pleomorphic Lobular Carcinoma

Abstract Context.—Lobular neoplasias (LNs) of the breast include atypical lobular neoplasia and lobular carcinoma in situ. Recent evidence suggests that LN is not only a risk factor for invasive lobular carcinoma, but is also a nonobligate precursor. Pleomorphic lobular carcinoma in situ (PLCIS) is a subtype of LN that has high-grade nuclei and other features that may mimic high-grade ductal carcinoma in situ. The management and follow-up of patients diagnosed with LN on core biopsy is a current issue of debate. However, recent genomic and molecular studies have identified candidate genes that may be important in understanding the pathogenesis of atypical lobular neoplasia and lobular carcinoma in situ, and thus may lead to other therapeutic interventions. Objective.—To review the literature on LN of the breast and discuss current issues in the diagnosis and management of this entity, with particular attention to the relatively newly recognized lesion PLCIS. Because the management of PLCIS varies from the other LN lesions, the recognition of PLCIS by the pathologist is necessary. Current issues in the molecular pathogenesis of LN are also presented. Data Sources.—Extensive review of the literature. Hematoxylin-eosin–stained and immunohistochemical-stained tissue from the author's personal collection. Conclusions.—Although morphology and immunohistochemical stains, such as E-cadherin, are important in the diagnosis and understanding of LN, genomic and molecular studies may guide the way these lesions are handled in the future. Recognizing PLCIS is important both for patient management and for our future understanding of LN pathogenesis.

scholarly journals Fibroadenoma containing lobular carcinoma in situ, an unusual finding in a normally benign mass

2020 ◽  
Vol 2020 (4) ◽  
Author(s):  
Christie M Brock ◽  
Charles Harper ◽  
Troy Tyler
Keyword(s):  
Carcinoma In Situ ◽  
Breast Tissue ◽  
Lobular Carcinoma ◽  
Left Breast ◽  
Lobular Carcinoma In Situ ◽  
Pathologic Evaluation ◽  
Benign Mass ◽  
Unusual Finding

Abstract This is the case of a 27-year-old female who underwent breast lumpectomy for fibroadenoma of the left breast. Pathologic evaluation of the specimen revealed lobular carcinoma in situ (LCIS) entirely confined to a large fibroadenoma without LCIS in the surrounding breast tissue.

scholarly journals Lobular neoplasia (so-called lobular carcinoma in situ) of the breast

Cancer ◽  
1978 ◽  
Vol 42 (2) ◽  
pp. 737-769 ◽  
Author(s):  
C. D. Haagensen ◽  
Nathan Lane ◽  
Raffaele Lattes ◽  
Carol Bodian
Keyword(s):  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Neoplasia ◽  
Lobular Carcinoma In Situ

Is Surgical Excision Necessary for the Management of Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ Diagnosed on Core Needle Biopsy?: A Report of 38 Cases and Review of the Literature

2008 ◽  
Vol 132 (6) ◽  
pp. 979-983 ◽  
Author(s):  
Joan Cangiarella ◽  
Amber Guth ◽  
Deborah Axelrod ◽  
Farbod Darvishian ◽  
Baljit Singh ◽  
...  
Keyword(s):  
Carcinoma In Situ ◽  
Invasive Carcinoma ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Surgical Excision ◽  
Lobular Neoplasia ◽  
Lobular Carcinoma In Situ ◽  
Radiologic Findings ◽  
Atypical Lobular Hyperplasia

Abstract Context.—Both atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) have traditionally been considered to be risk factors for the development of invasive carcinoma and are followed by close observation. Recent studies have suggested that these lesions may represent true precursors with progression to invasive carcinoma. Due to the debate over the significance of these lesions and the small number of cases reported in the literature, the treatment for lobular neoplasia diagnosed by percutaneous core biopsy (PCB) remains controversial. Objective.—To review our experience with pure LCIS or ALH diagnosed by PCB and correlate the radiologic findings and surgical excision diagnoses to develop management guidelines for lobular neoplasia diagnosed by PCB. Design.—We searched the pathology database for patients who underwent PCB with a diagnosis of either pure LCIS or ALH and had subsequent surgical excision. We compared the core diagnoses with the surgical excision diagnoses and the radiologic findings. Results.—Thirty-eight PCBs with a diagnosis of ALH (18 cases) or LCIS (20 cases) were identified. Carcinoma was present at excision in 1 (6%) of the ALH cases and in 2 (10%) of the LCIS cases. In summary, 8% (3/38) of PCBs diagnosed as lobular neoplasia (ALH or LCIS) were upgraded to carcinoma (invasive carcinoma or ductal carcinoma in situ) at excision. Conclusions.—Surgical excision is indicated for all PCBs diagnosed as ALH or LCIS, as a significant percentage will show carcinoma at excision.

Lobular Neoplasia: Morphology and Management

2014 ◽  
Vol 138 (10) ◽  
pp. 1344-1349 ◽  
Author(s):  
Julie Jorns ◽  
Michael S. Sabel ◽  
Judy C. Pang
Keyword(s):  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Treatment Strategies ◽  
Lobular Neoplasia ◽  
Lobular Carcinoma In Situ ◽  
National Guidelines ◽  
Diagnostic Challenge ◽  
Pleomorphic Lobular Carcinoma

Context.—Lobular neoplasia encompasses a spectrum of disease, including atypical lobular hyperplasia and lobular carcinoma in situ. Although classic forms of lobular neoplasia are predominantly heralded as a risk marker, the pleomorphic form of lobular carcinoma in situ is generally regarded as a more aggressive subtype and a possible cancer precursor, and thus is treated in a manner more similar to ductal carcinoma in situ than classic forms of lobular neoplasia. Objective.—To focus on the morphologic spectrum of lobular neoplasia as highlighted by 3 cases and current management recommendations. Areas of diagnostic challenge and controversy are addressed. Data Sources.—A review of the pertinent published literature and current national guidelines was conducted. Conclusions.—Correct classification of classic lobular neoplasia and pleomorphic lobular carcinoma in situ is critical because of differences in clinical management, with current treatment strategies focused on risk reduction for patients with classic lobular neoplasia and eradication of the lesion for those with pleomorphic lobular carcinoma in situ.

Sign in / Sign up

Export Citation Format

Share Document